Overview
Medis Poland supports pharmaceutical and biotechnology companies with product commercialization in Central and Eastern Europe. Its services include marketing and sales, market access and pricing, medical and regulatory affairs, pharmacovigilance, supply chain, quality assurance, and financing.
Financials
Revenue history (in k)
Filing timeliness
Financial statements were filed on time, on average 12 days early.
- 202510/07/2026
- 202410/07/2025
- 202320/06/2024
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
30 Percent Revenue Growth in the First Half of the Year Across Our Markets
Medis recorded 30% revenue growth in the first half of the year, driven by international expansion and new speciality medicines across Central and Eastern Europe.
Medis Receives Two Awards at Compliance Conference 2026
Medis received two awards at Compliance Conference 2026: Best Compliance Program and Best Compliance Manager of the Year.
Novalac Aminova Receives Product of the Year Award
Novalac Aminova has received the 2026 Product of the Year Award in the "Foods for Special Medical Purposes" category at the Bulgarian Pharmaceutical Days.
Researchers Invited to Apply for the 13th International Medis Awards
Applications are open for the 13th International Medis Awards for Medical Research, recognizing outstanding researchers in Central and Eastern Europe.
Talk to Your Colleagues as Much as Possible
An interview by MQ Magazine with Tone Strnad, recipient of the Lifetime Achievement Award in Management, founder and long-standing Director of Medis.
The Highest Dun & Bradstreet Rating of 5A1 for Medis
Medis has achieved the Dun & Bradstreet 5A1 rating, confirming exceptional financial strength, minimal business risk and long-term reliability as a trusted partner.
Industry
Offer
- Specialty medicines
- Orphan drugs
- Medical technologies
- Consumer health products
- Pharmaceutical marketing
- Pharmaceutical market access
- Supply chain management
Website technology
- Analytics and marketing
- Google Tag Manager
Authorized Representatives
Manner of representation
Each member of the management board is independently authorized to submit declarations of will on behalf of the company and to represent the company, also in the case of a multi-member management board.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Medis Farmacevstka Družba , D.o.o., | 100 | $1,350.62 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2024-06-01.
15 1020 1026 0000 1902 0607 0868- 47 1020 1026 0000 1402 0606 4135
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Ideal Polandsp. z o.o. | $1,092,652.45 | ideal-poland.pl | ||
| Polymedtechsp. z o.o. | $1,074,409.20 | polymedtech.pl | ||
| Kleemed Pharmaceuticals Polandsp. z o.o. | $847,166.12 | kleemed.com.pl | ||
| Goodwill Pharma Polskasp. z o.o. | $664,724.30 | goodwillpharma.com | ||
| Support-Pharmasp. z o.o. | $521,132.71 | support-pharma.pl | ||
| Silesia Farmsp. z o.o. | $443,798.55 | silesiafarm.pl | ||
| Pharmagetsp. z o.o. | $389,817.77 | pharmaget.pl | ||
| Medcellsp. z o.o. | $339,369.93 | medcell.pl | ||
| Effective Pharmsp. z o.o. | $246,062.91 | effectivepharm.pl | ||
| Biuro Handlowe Mar Polsp. z o.o. | $204,064.87 | biurohandlowe.com |
FAQ
Last updated: 2026-10-07